Responses
Immune cell therapies and immune cell engineering
Original research
Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial
Compose a Response to This Article
Other responses
No responses have been published for this article.
